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Abstract
Background: Smoking cessation is the best possible way to prevent the progression of smoking related airway
diseases. However, the effect and time scale of smoking cessation on airway inflammation/remodelling are largely
unknown. This prospective study evaluated the effects of smoking cessation on induced sputum (IS) neutrophils,
matrix metalloproteinases (MMP-7, -8, -9) and tissue inhibitor of metalloproteinase-1 (TIMP-1).
Methods: A total of 61 subjects participated in the study; 17 stopped smoking for 3 months and 9 for 6 months.
The proportion of IS neutrophils and the levels of MMPs and TIMP-1 by ELISA were determined at baseline and at
3 and 6 months after cessation.
Results: In the smokers, baseline IS neutrophils, MMPs and TIMP-1 were significantly higher compared to non-
smokers. Levels of MMP-7, -8 and TIMP-1 decreased nearly to those of non-smokers but the levels of MMP-9
increased significantly from the baseline of the same subjects at 3 months after cessation (p = 0.009) with no
significant decline at 6 months after cessation.
Conclusions: Sputum MMP-9 remained elevated after 6 months of smoking cessation, which may contribute to
ongoing lung damage typical of COPD.
Background
Chronic obstructive pulmonary disease (COPD) is one
of the most important causes of death all over the world
[1]. Smoking is the single most important risk factor of
COPD and smoking cessation the only intervention that
is able to reduce the disease progression [2,3]. Smoking
asthmatics have been excluded from most investigations,
but it is known that the inflammatory profile in these
subjects is very similar to COPD, with one of the most
important features being the influx of neutrophils to the
airways in asthma [4]. There is a remarkable overlap in
many features in smokers with asthma and subjects with
COPD; recent studies even suggest that the majority of
older people may suffer from both asthma and COPD
[5]. It is not known how the smoking cessation exactly
changes the airway inflammatory processes in chronic
smokers with or without asthma or COPD.
The very few available studies appear to indicate that
airway inflammation and oxidative stress persists after
smoking cessation over months in subjects with chronic
bronchitis and COPD [6-8]. Evidence of ongoing inflam-
mation has been documented via the increased levels of
neutrophils and eosinophils in bronchoalveolar lavage
(BAL) fluid, CD4+ and CD8+ cells in bronchial biopsy
specimens and eosinophilic cationic protein (ECP) in
sputum. The majority of the studies assessing the effects
of smoking cessation on airway inflammation have been
cross-sectional and there is a lack of prospective
investigations.
Extracellular matrix (ECM) deposition is one patholo-
gical form of the tissue remodelling detected in the air-
ways [2,9,10]. Matrix metalloproteinases (MMPs) have
an important role in the breakdown of ECM and they
are considered as biomarkers of tissue damage in several
smoking related lung diseases [10-12]. Over 30 MMPs
have been characterized, many of which are activated by
smoking and/or oxidative stress [13,14]. The levels of
MMP-8 and -9 have been shown to be elevated in both
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experimental emphysema and COPD [10,15,16]. Levels
of MMPs on sputum, mainly MMP-9, are also elevated
in asthma when compared to the controls [17]. TIMP-1
(tissue inhibitor of metalloproteinases-1) is the major
endogenous inhibitor of MMP-8 and -9, and the levels
of this protein are elevated in COPD [15]. MMP-7 is
produced by alveolar macrophages, breaks down elastin
and has an important role in the maintenance of innate
immunity proteolytically activating anti-bacterial pep-
tides in the lung [12]. Its role in asthma and COPD
remains to be clarified [10,17].
Induced sputum (IS) collection is a non-invasive
method for assessment of airway inflammation in the
airways. In the future, useful biomarkers may also be
identified in IS, to permit accurate determination of the
many phenotypes of smoking-related diseases [18,19].
This prospective study was undertaken to assess if
smoking cessation is associated with changes in num-
bers of neutrophils, and the levels of MMP-7, -8, -9 and
TIMP-1 in induced sputum specimens. Inflammatory
markers were determined at baseline and at three and
six months after quitting of smoking to better under-
stand the time course of smoking related alterations and
possible temporal differences in the levels of the MMPs.
The results were also compared to the corresponding
values obtained from non-smoking controls. This is the
first prospective study where the effects of smoking ces-
sation on human MMPs have been assessed.
Methods
Subjects
Originally, 61 volunteer individuals consisting of 25
asymptomatic smokers, 15 smokers with mild asthma
defined according to GINA [20], 7 with chronic bron-
chitis (previous Stage 0 COPD by GOLD criteria i.e.
symptomatic smokers) and 14 subjects with GOLD
Stage 1-2 COPD [1,21] were recruited to the study.
There were 11 asthmatics and two subjects with COPD
using inhaled steroids (daily doses ranging from 400 to
2000 μg). All the asthmatics and five subjects with
COPD had short-acting b2-agonists as rescue medicine.
The subjects were advised to terminate smoking by a
research nurse and were provided available pharmaceu-
tical therapies i.e. nicotine products and bupropion to
support their abstinence, based on the instructions by
the physicians. Smoking cessation was confirmed by
exhaled carbon monoxide analysis. The group of non-
smokers included never smokers or ex-smokers who
had stopped smoking at least 20 years previously. Three
of the smokers, three of the COPD patients and 6 asth-
matics revealed at least one positive reaction in the skin
prick test analyses for common aeroallergens (birch,
grass, mugwort, Cladosporium herbarum, cat, dog,
horse, and the house dust mite Dermatophagoides ptero-
nyssinus). The subject characteristics of the smokers and
non-smokers, who were also included in the study, are
given in Table 1.
The study protocol was accepted by the Ethics Com-
mittees of the Helsinki University Hospital and the
Southampton University Hospital, and it was performed
according to principles of Helsinki Declaration [22]. The
subjects provided a written permission for participating
in the study.
Lung function tests
Standard spirometric values (Medikro M 904, Kuopio,
Finland) were performed according to ATS/ERS recom-
mendations [23]. Reference values compiled by Viljanen
et al. [24] for Finnish population were used.
Sputum induction
As recommended by the ERS Task Force, the subjects
inhaled hypertonic saline in order to provoke IS produc-
tion [18]. Four volumes of dithioerythritol (DTE, Sigma,
Table 1 Subject characteristics of all the patients recruited for the smoking cessation.
Non-smoking controls Asymptomatic Smokers Smokers with smokers Chronic asthma bronchitis/COPD
Subjects (n) 30 25 15 21
Female/male 7/23 15/10 9/6 14/7
Age yrs 56 ± 8 42 ± 12 42 ± 12 56 ± 10
Pack-yrs 4 ± 8 23 ± 15 22 ± 14 39 ± 15
Post-bronchodilator
FVC L** 4.9 ± 0.71 3.9 ± 0.60 4.2 ± 0.70 3.0 ± 0.66
FVC % pred 102 ± 9 99 ± 14 103 ± 17 102 ± 38
FEV1 L** 4.0 ± 0.65 3.2 ± 0.49 3.5 ± 0.55 2.1 ± 0.72
FEV1% pred* 104 ± 12 97 ± 8 99 ± 14 79 ± 8
FEV1/FVC 82 ± 4.4 83 ± 1 80 ± 9 69 ± 15
Data presented as mean ± SD or median (range). FVC: forced vital capacity; % pred: % predicted; FEV1: forced expiratory volume in one second; *: p < 0.01; **: p
< 0.001. #: baseline levels at once after smoking cessation.
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Germany) were added as the weight of the sample. The
supernatant was frozen at -80°C for biochemical ana-
lyses. Cell viability was studied by Trypan blue in a Bur-
ker chamber.
Cytocentrifuge preparations were made by Cytospin
(Shandon Cytospin 3) and centrifuged at 450 rpm for 6
minutes. The slides were stained by May-Grunwald-
Giemsa-staining (Merck, Germany) for cell differential
counts with 400 cells being counted from each slide. If
the samples had less than 70% of squamous epithelial
cells they were accepted for further assessments. The
slides were frozen at -20°C.
The IS levels of MMP-7, -8, -9 and TIMP-1 were stu-
died at the onset of smoking cessation and three and six
months later. The numbers of neutrophils were assessed
at the same time points.
MMP-7, MMP-8, MMP-9 and TIMP-1 analyses
MMP-7, MMP-8, MMP-9 and TIMP-1 concentrations
were analysed by commercial ELISA kits (Amersham
Biosciences, Cardiff, UK) according to the manufac-
turer’s instructions. The detection limits were 0.016 ng/
ml for MMP-7, 0.032 ng/ml for MMP-8, 0.6 ng/ml for
MMP-9 and 3.13 ng/ml for TIMP-1.
Statistical methods
The data are given as means (standard deviation) or
medians (range). Values between groups were analysed
with Mann-Whitney U and Kruskal-Wallis tests. The
differences in MMP levels between two time points
(baseline vs. three months after smoking cessation, base-
line vs. six months after cessation, three months vs. six
months after cessation) were analysed by Wilcoxon
signed rank test. The data were analysed by SPSS for
Windows 15.0 (SPSS Inc., Chicago, IL, USA) and a p-
value < 0.05 was considered statistically significant.
Results
There were 17 subjects who successfully stopped smok-
ing for a time of three months and 9 for half a year.
Characteristics of these subjects are given in Table 2. Of
these 17 individuals, six were asymptomatic smokers,
four had mild asthma and seven were suffering from
chronic bronchitis or COPD (one with previous GOLD
Table 2 Subject characteristics of the patients who quitted smoking.
Asymptomatic smokers Smokers with asthma Chronic bronchitis/COPD
Subjects (n)
3 mo 6 4 7
6 mo 4 4 1
Female/Male
3 mo 3/3 3/1 4/3
6 mo 3/1 3/1 1/0
Age yrs
3 mo 47 ± 6 46 ± 2 59 ± 11
6 mo 50 ± 5 46 ± 2 57
Pack-yrs
3 mo 15 ± 10 21 ± 18 36 ± 14
6 mo 19 ± 11 21 ± 18 21
Post-bronchodilator
FVC L
3 mo 4.2 ± 0.65 3.7 ± 0.68 2.9 ± 0.48
6 mo 3.9 ± 0.67 3.7 ± 0.68 3.5
FVC % pred
3 mo 95 ± 6 99 ± 27 85 ± 9
6 mo 96 ± 6 99 ± 27 83
FEV1 L
3 mo 3.5 ± 0.68 3.0 ± 0.53 2.1 ± 0.43
6 mo 3.2 ± 0.71 3.0 ± 0.53 2.35
FEV1% pred
3 mo 96 ± 5 98 ± 26 75 ± 8
6 mo 97 ± 6 98 ± 26 70
FEV1/FVC
3 mo 83 ± 4 82 ± 2 71 ± 7
6 mo 82 ± 5 82 ± 2 82 ± 2
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Stage 0 and six with Stage 1 i.e. mild COPD). Four
asymptomatic smokers, four asthmatic individuals and
one subject with COPD succeeded in quitting smoking
for six months. All subjects who completed the study
had measurements at baseline and at 3 and 6 months.
Due to the high number of dropouts, the three sub-
groups became small. The subjects in these subgroups
were either asymptomatic or symptomatic smokers, or
had mild asthma or mild COPD. Therefore, in the
MMP analyses these three groups were assessed as a
single group. The inflammatory profile in the sputum of
these smokers revealed neutrophil predominance. In
smokers and in non-smokers the percentages of neutro-
phils and the total count for neutrophils were 54.5 ±
18.7% vs 30.0 ± 12.0% and 2.2 ± 3.1 (10^6 cells/ml) vs
0.42 ± 0.55 (×10^6 cells/ml), respectively. The levels of
the MMP-7, -8, -9 and TIMP-1 in smokers and non-
smokers were 12.7 ± 11.5 ng/ml vs 1.7 ± 0.96 ng/ml,
91.7 ± 113.5 ng/ml vs 22.0 ± 29.3 ng/ml, 50.1 ± 63.2
ng/ml vs 21.9 ± 11.9 ng/ml and 1383.3 ± 1322.2 ng/ml
vs 822.3 ± 582.7 ng/ml, respectively. Baseline proportion
of neutrophils and the levels of the MMPs and TIMP-1
were significantly higher in smokers compared to those
of non-smokers in a cross sectional setting (p = 0.021, p
= 0.014, p = 0.001, p = 0.02, p = 0.006, respectively).
The IS neutrophil proportions increased significantly
at 3 months after smoking cessation; 67.5 ± 13.7%, 2.9 ±
2.6 × 10^6 cells/ml (p = 0.035), but at 6 months the dif-
ference from non-smokers was no longer statistically
significant (38.2 ± 14.4%, 0.74 ± 0.83 × 10^6 cells/ml)
(Figure 1). The individual levels of MMP-7, -8 and
TIMP-1 at 3 months after cessation did not change sig-
nificantly from the corresponding baseline levels of
these same subjects. The corresponding individual levels
after smoking cessation at 6 months decreased signifi-
cantly compared to the baseline (p = 0.032, p = 0.001, p
= 0.04, respectively) (Figures 2, 3, 4 and 5). They also
decreased nearly to the levels of non-smokers in the
cross sectional evaluation, though there was high varia-
bility in the TIMP-1 levels. In contrast, the individual
levels of MMP-9 increased significantly from the base-
line at 3 months after cessation (p = 0.009) and did not
differ significantly at 6 months after the cessation when
compared to the baseline levels in these same
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Figure 1 The percentage of induced sputum (IS) neutrophils in the smoking cessation group (n = 17, see Table 2) at the onset of
smoking cessation (baseline) and at 3 and 6 months after stopping smoking. IS neutrophils were significantly higher in the smoking
cessation group at the baseline compared to the non-smokers (p = 0.021). Neutrophils increased significantly from baseline at 3 months after
cessation (p = 0.035) and declined to the levels of non-smokers at 6 months after the cessation.
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individuals (p = 0.069), and the differences were even
more significant when compared to the non-smokers in
a cross sectional evaluation (p = 0.017).
Discussion
As far as we are aware, this is the first prospective study
to examine how smoking cessation is reflected in the
levels of sputum MMPs. Most previous smoking cessa-
tion studies have been cross-sectional and the real
effects of smoking cessation on airway remodelling pro-
cesses/tissue destruction have remained unclear. Based
on this study, it seems that sputum MMP levels gener-
ally decline slowly after smoking cessation. However, the
elevated levels of MMP-9 in smokers are sustained for
many months after giving up smoking for reasons that
remain unclear.
Smoking cessation reduces COPD morbidity, hospital
admissions [25] and COPD progression [1]. It has also
been shown that symptoms decrease significantly after a
month of quitting of smoking [8]. The decline of lung
function is attenuated slowly, only after 2-3 years from
smoking cessation [26,27]. Smoking evokes very similar
airway pathology in asthma and COPD, with the typical
features being the recruitment of increased numbers of
neutrophils to the airways and elevated oxidative stress
[4,8]. In this study, smoking resulted in neutrophil predo-
minance and elevation of several MMPs in the IS of smo-
kers with or without mild airway disease as compared to
the situation in non-smokers. The fact that MMP-9
increased from the baseline during the 3-6 months after
smoking cessation suggests that extracellular matrix
breakdown continue in the airways for several months
after an individual stops smoking. Since neutrophils are
an important source of MMP-9, it could be argued that
the elevated level of this MMP is simply a marker of neu-
trophilic inflammation. However, the finding of the per-
sistently elevated MMP-9 levels after 6 months at a time
when the neutrophil counts had returned to those
encountered in non-smokers suggests that the rise in
MMP-9 is not dependent on the numbers of neutrophils
per se but instead reflects increased MMP-9 release. Our
recent studies have shown that the elevated levels of
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Figure 2 The levels of MMP-7 in the smoking cessation group at the baseline and at 3 and 6 months after stopping smoking. The
levels of MMP-7 were significantly higher in the smoking cessation group at the baseline compared to the non-smokers (p = 0.014). MMP-7
declined to the levels of non-smokers at 6 months after the cessation.
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MMP-9 are associated with increased MMP-9 activity
[16,28]. However, Lowrey et al. [29] have reported that
MMP-9 protein but not MMP activity is higher in spu-
tum of smokers with COPD when compared to smokers
without COPD. The significance of MMP-9 in the air-
ways needs further investigations, since it has also been
suggested that MMP-9 may have protective role at least
against ozone induced airway inflammation [30]. It needs
to be emphasized also that our results are preliminary
and final conclusions about the significance of sputum
MMP-9 after smoking cessation remain unclear.
All of the other markers studied had returned to the
levels of non-smokers by 6 months after cessation,
which suggests that significant repair of tissue damage
elicited by smoking has been initiated. A previous study
noted that inflammatory markers such as macrophages
and IL-8 declined significantly in asymptomatic smokers
one year after smoking cessation [31]. This is in agree-
ment with our results showing that MMP-7, -8 and
TIMP-1 though its’ variability can return to normal
levels within 6 months after the patients successfully
quits smoking. Baseline proportion of neutrophils and
the levels of MMPs and TIMP-1 were significantly
higher in smokers compared to those of non-smokers.
These findings are in full agreement with the studies
reporting that MMP-8, -9 and TIMP-1 are elevated in
COPD and that the increased levels are related to smok-
ing [10,16,32] and also that the disease itself, not only
smoking, results in MMP elevation [33-35]. MMP-7 is
induced by hypoxia [36] but, as far as we are aware, this
is the first study showing that MMP-7 elevation is pro-
voked by smoking. MMP-7 is expressed by macrophages
and expression is upregulated also in pulmonary epithe-
lial cells in the presence of chronic infection, which
might support the hypothesis that MMP-7 contributes
to pulmonary immunity [37] and that smoking cessation
decreases the chronic inflammation in the airways.
One weakness of this study was the high number of
dropouts, despite our best efforts, only 15% of our sub-
jects were still non-smoking six months later. This
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Figure 3 The levels of MMP-8 in the smoking cessation group at the baseline and at 3 and 6 months after stopping smoking. The
levels of MMP-8 were significantly higher in the smoking cessation group compared to the non-smokers (p = 0.001). MMP-8 declined to the
levels of non-smokers at 6 months after the cessation.
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Figure 4 The levels of MMP-9 in the smoking cessation group at the baseline and at 3 and 6 months after stopping smoking. The
levels of MMP-9 were significantly higher in the smoking cessation group compared to the non-smokers (p = 0.02). MMP-9 levels remained
elevated in the smoking cessation group when compared to the levels of non-smokers at 6 months after the cessation (p = 0.017).
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Figure 5 The levels of TIMP-1 in the smoking cessation group (n = 17) at the baseline and at 3 and 6 months after stopping smoking.
The levels of TIMP-1 were significantly higher in the smoking cessation group compared to the non-smokers (p = 0.006). TIMP-1 declined to the
levels of non-smokers at 6 months after the cessation.
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considerable numbers of the dropouts was to be antici-
pated taking into account the well-known difficulties
associated with smoking cessation. In the study of Kaper
et al. [38], for example, subjects receiving reimbursed
smoking cessation treatment had an abstinence rate of
5.5% half a year after the interventions. In the present
study, the cases from different subgroups were com-
bined, which was also justified for several reasons i.e.
the subjects were smokers who had no airway disease or
the disease was mild. Smoking asthmatics also develop
airway neutrophilia in a similar manner as smokers and
subjects with COPD, and the same phenomenon was
found in this study. Moreover, the differentiation of
symptomatic smokers from mild COPD, and smoking
asthmatics from COPD is a demanding task since there
is a clear overlap in the cell profiles and diseases [4,8].
In our study, also the MMP levels were overlapping in
these subgroups of smokers as expected. The high num-
ber of dropouts diminishes the power of this study, why
these results, though important, require further investi-
gations with larger numbers of patients with various
phenotypes of asthma and COPD.
Conclusions
In summary, our study clearly suggests that the high
levels of MMP-9 in the airways persist for at least 6
months after smoking cessation, and this does not
appear to be related to the numbers of inflammatory
cells in the airways. It is still unclear whether MMP-9 is
one of the instigators to the ongoing disease progression
in some individuals after smoking cessation or whether
it has a protective role in airway inflammation.
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